论文部分内容阅读
目的探讨肝素在防治紫癜性肾炎中的应用。方法选自2006年1月至2008年1月住院的90例过敏性紫癜患儿,随机分为治疗组45例,对照组45例。结果治疗组皮疹消退时间3~6 d,对照组为3~12 d;关节肿瘤消失时间治疗组为1~2 d,对照组为1~4 d;治疗组消化道症状消失时间2~3 d,对照组为2~5 d;HSPN发生率治疗组为5例,对照组为9例;应用肝素治疗期间未见出血、皮疹、肝功能受损及血小板减少等毒副作用。结论过敏性紫癜应用肝素后,治疗组与对照组存在明显差异.说明在治疗过敏性紫癜患儿时,应及早应用肝素,以减少紫癜性肾炎的发展。
Objective To investigate the application of heparin in the prevention and treatment of purpuric nephritis. Methods 90 children with Henoch-Schonlein purpura who were hospitalized from January 2006 to January 2008 were randomly divided into treatment group (45 cases) and control group (45 cases). Results The treatment group rash subsided time 3 ~ 6 d, the control group was 3 ~ 12 d; disappearance of joint tumor treatment group for 1 ~ 2 d, control group for 1 ~ 4 d; treatment group disappearance of digestive symptoms 2 ~ 3 d , And the control group was 2 ~ 5 days. The incidence of HSPN was 5 cases in the treatment group and 9 cases in the control group. No bleeding, rash, impaired liver function and thrombocytopenia were observed during heparin treatment. Conclusion Heparin is used in the treatment of Henoch-Schonlein purpura, and there is a significant difference between the treatment group and the control group, indicating that heparin should be used as early as possible in the treatment of Henoch-Schonlein purpura to reduce the development of purpuric nephritis.